Stephen Mahoney
2022 - Dianthus Therapeutics
In 2022, Stephen Mahoney earned a total compensation of $1.1M as Former President, Chief Financial and Operating Officer at Dianthus Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $188,160 |
|---|---|
| Option Awards | $483,680 |
| Salary | $448,000 |
| Other | $1,047 |
| Total | $1,120,887 |
Mahoney received $483.7K in option awards, accounting for 43% of the total pay in 2022.
Mahoney also received $188.2K in non-equity incentive plan, $448K in salary and $1K in other compensation.
Rankings
In 2022, Stephen Mahoney's compensation ranked 2,807th out of 5,732 executives tracked by ExecPay. In other words, Mahoney earned more than 51.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,807 out of 5,732 | 51st |
Division Manufacturing | 1,568 out of 3,121 | 50th |
Major group Chemicals And Allied Products | 727 out of 1,416 | 49th |
Industry group Drugs | 679 out of 1,317 | 48th |
Industry Pharmaceutical Preparations | 492 out of 963 | 49th |
Source: SEC filing on April 11, 2024.
Mahoney's colleagues
We found two more compensation records of executives who worked with Stephen Mahoney at Dianthus Therapeutics in 2022.
News
Signal Genetics CEO Scott Myers receives $36M in 2023
April 26, 2024
Dianthus Therapeutics Former President, Chief Financial and Operating Officer Stephen Mahoney's 2023 pay jumps 48% to $1.7M
April 11, 2024
Kiniksa Pharmaceuticals, Ltd. CEO Sanj Patel's 2019 pay falls 35% to $4.8M
April 28, 2020
Kiniksa Pharmaceuticals, Ltd. CEO Sanj Patel's 2018 pay jumps 389% to $7.3M
April 17, 2019